KI and WU Polyomaviruses in Patients Infected with HIV-1, Italy by Babakir-Mina, Muhammed et al.
LETTERS
	 Emerging	Infectious	Diseases	•	www.cdc.gov/eid	•	Vol.	15,	No.	8,	August	2009	 1323 
Our patient likely had rickettsial 
infection  acquired  in  Honduras.  We 
present this case to alert clinicians to 
consider the diagnosis of rickettsial in-
fections in the Americas, even if infec-
tions have not been previously docu-
mented in a specific country or region. 
Because rickettsial infections can be 
severe and are treatable, the clinician 
should consider rickettsial infections 
in returned travelers with compatible 
clinical findings. Our case also dem-
onstrates the potential role of travel-
ers as sentinels of emerging infectious 
diseases.
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KI and WU  
Polyomaviruses in 
Patients Infected 
with HIV-1, Italy
To the Editor: Before 2007, two 
human polyomaviruses were known to 
infect humans: BK virus and JC virus 
(1,2).  Recently,  2  novel  polyomavi-
ruses, KI polyomavirus (KIPyV) and 
WU  polyomavirus  (WUPyV),  were 
identified in the respiratory secretions 
of children with signs of acute respira-
tory signs (3,4); little evidence exists 
to suggest that these viruses are caus-
ative agents of respiratory tract disease 
(5).  To  determine  the  prevalence  of 
WUPyV and KIPyV in the plasma of 
HIV-1–infected patients, we screened 
62 persons who were HIV-1 positive 
by using PCR to detect the 2 viruses. 
We also conducted phylogenetic anal-
ysis of the identified strains.
Plasma specimens were collected 
at Istituto di Ricovero e Cura a Carat-
tere Scientifico Instituto Fisioterapico 
Ospetaliere–San  Gallicano  Institute 
and Tor Vergata University Hospital, 
Rome, Italy, from April 2005 through 
September 2008. Patients were adults 
(37–54 years of age, median age 45.5 
years)  and  were  being  treated  with 
antiretroviral drugs. HIV-1 viral load 
determination,  CD4+  counts,  and 
HIV-1 genotyping were performed as 
part of the routine investigation. Plas-
ma  viremia  levels  ranged  from  <50 
to  2,877,764  copies/mL,  and  CD4+ 
counts  ranged  from  150  to  1,218. 
Most patients (64.5%) were infected 
by HIV-1 subtype B. Other subtypes 
found were F, G, and C.
Total DNA was extracted from 0.2 
mL of plasma by using the QIAamp 
DNA Mini Kit according to the man-
ufacturer’s  instruction  (QIAGEN   
S.p.A., Milan, Italy) and then stored 
at  –80ºC  until  analysis.  KIPyV  and 
WUPyV  PCR  screening  was  carried 
out  as  described  (3,4).  Positive  iso-
lates  were  reamplified  with  primers 
encompassing the N-terminal part of 
the large T antigen (T-Ag) and almost 
the entire small t antigen (t-Ag) genes. 
KIPyV was amplified as described (6), 
and,  for  WUPyV,  the  primers  were 
FWUV4460  5 ′-ACTGAGACCAC-
CAGTAATCCCAG-3 ′  (4460–4482 
nt) and RWUV5200 5 ′-AAGCAGAG-
GGCCTTGCTGAGGCG-3 ′  (5200–
5178 nt). The thermal cycling profile 
was 1 cycle at 94ºC for 10 min and 
then 40 cycles at 94ºC for 30 s, at 65ºC 
for 30 s, and at 72ºC for 60 s. The am-
plified t-Ag fragments were sequenced 
as  described  (6).  The  obtained  se-
quences (KIV-RM21, KIV-RM22, and 
WU-IT3) were submitted to GenBank 
(accession nos. FJ842112–FJ842114) 
and  matched  against  all  deposited 
sequences  (www.ncbi.nlm.nih.gov/
BLAST).  ClustalX  software  (http://
bips.u-strasbg.fr/fr/documentation/LETTERS
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clustalx/#g) was used to obtain align-
ment with a set of KIPyV and WUPyV 
isolates  from  Italy  (6,7)  (accession 
nos. FJ389513–FJ389516, FJ594120–
FJ594126,  FJ594118,  FJ594119, 
FJ804123,  FJ811519–FJ811524, 
FJ824854, and FJ821706) and proto-
type  strains  for  KIPyV  (EF127906, 
EF127908,  and  EF520288)  and  for 
WUPyV  (EF444549–EF444554, 
EU711054–EU711058,  EU296475, 
EU358768,  and  EU358769).  Align-
ment  was  manually  edited  with  the 
Bioedit  software  (www.mbio.ncsu.
edu/BioEdit/bioedit.html)  (6).  Posi-
tions  containing  gaps  were  removed 
from  the  final  alignment.  For  our 
dataset, the best fitting nucleotide sub-
stitution model was tested with a hi-
erarchical likelihood ratio test follow-
ing  the  strategy  described  (6),which 
used  a  neighbor-joining  (NJ)  base 
tree with LogDet-corrected distances 
(http://paup.csit.fsu.edu/about.html). 
Maximum-likelihood (ML) trees were 
then inferred with the selected model 
and ML-estimated substitution param-
eters. The heuristic search for the ML 
tree was performed by using an NJ tree 
as starting tree and the tree–bisection-
reconnection  branch-swapping  algo-
rithm.  NJ  trees  were  also  estimated 
by  using  pairwise  distances  inferred 
by ML with the best fitting nucleotide 
substitution model. Calculations were 
performed  by  using  PAUP*  4.0b10 
(http://paup.csit.fsu.edu/about.html) 
(6).  Statistical  support  for  internal 
branches in the NJ trees was obtained 
by  bootstrapping  (1,000  replicates) 
and with the ML-based, zero–branch-
length test for the ML trees (6).
Of 62 plasma specimens screened, 
PCR detected KIPyV in 2 (3.2%) and 
WUPyV  in  1  (1.6%). All  3  patients 
were  infected  by  HIV-1  subtype  B. 
Phylogenetic analysis of the t-Ag of 
the 3 isolates showed that KIV-RM21 
and  KIV-RM22  are  not  closely  re-
lated to the KIPyVs isolated in Italy 
from feces (KIV-RM5 to KIV-RM11), 
respiratory  tract  (KIV-RM1  to  KIV-
RM4), and tonsils (KIV-RM12 to KIV-
RM20), nor are they related to those 
previously identified (6,7). Similarly, 
WUV-IT3  was  not  related  to WUV-
IT1  or  WUV-IT2  nor  to  WUPyVs 
identified in stool and respiratory tract 
secretions (Figure).
To date, KIPyV  and WUPyV have 
been detected in respiratory secretions 
and stool and serum specimens from 
pediatric patients with acute respira-
tory symptoms and have been found 
in respiratory tissue of adults and chil-
dren (3,4,6,8). Few data are available 
on  the  detection  and  reactivation  of 
these novel polyomaviruses in immu-
nocompromised patients (9,10). In this 
study, KIPyV and WUPyV sequences 
were  found  in  3.2%  and  1.6%  of   
HIV-1–infected patients, respectively. 
None of the patients had respiratory 
symptoms, so the presence of the 2 vi-
ruses in plasma raises the question of 
whether they play a pathogenic role in 
immunocompromised patients.
Molecular analysis of the KIPyV   
and  WUPyV  identified  in  plasma 
showed  that  these  polyomaviruses 
were  not  closely  related  to  strains 
identified previously in other countries 
nor to the KIPyVs and WUPyVs iden-
tified in Italy in stool, respiratory tract 
tissue, and tonsils. Whether this differ-
ence reflects a tropism of some strains 
for a particular tissue or organ remains 
to be established. Further studies are 
needed to clarify the possible patho-
Figure.	Unrooted	phylogenetic	tree	showing	analysis	of	KI	(KIV-RM21,	KIV-RM22)	and	WU	
(WUV-IT3)	polyomaviruses	(KIPyVs,	WUPyVs,	respectively)	identified	in	the	plasma	of	HIV-
1–positive	patients.	The	identified	strains	are	indicated	in	boldface,	and	the	phylogenetic	
analysis	refers	to	the	small	t	region.	The	other	polyomaviruses	shown	in	the	figure	are	the	
KIPyVs	(KIV-RM1	to	KIV-RM20)	and	WUPyVs	(WUV-IT1	and	WUV-IT2)	identified	in	Italy	
in	previous	studies	(6,7)	and	the	prototype	strains	for	KIPyV	(GenBank	accession	nos.	
EF127906,	EF127908,	EF520288)	and	WUPyV	(GenBank	accession	nos.	EF444549–
EF444554,	 EU711054–EU711058,	 EU296475,	 EU358768,	 and	 EU358769).	 GenBank	
accession	numbers	for	all	virus	strains	are	shown	in	parentheses.	Multiple	nucleotide	
sequence	alignments	were	performed	by	using	ClustalX	software	(http://bips.u-strasbg.
fr/fr/documentation/clustalx/#g),	and	the	phylogenetic	tree	was	constructed	by	using	the	
neighbor-joining	algorithm	with	LogDet-corrected	distances	(http://paup.csit.fsu.edu/about.
html)	(8).	An	asterisk	(*)	beside	a	branch	represents	significant	statistical	support	for	the	
clade	 subtending	 that	 branch	 (p<0.001	 in	 the	 zero-branch–length	 test)	 and	 bootstrap	
support	>75%.	Scale	bar	indicates	nucleotide	substitutions	per	site.LETTERS
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genic role of KIPyV and WUPyV in 
immunocompromised patients.
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Extreme Drug  
Resistance in 
Acinetobacter  
baumannii  
Infections in  
Intensive Care 
Units, South Korea
To  the  Editor:  Acinetobacter 
spp.  have  emerged  as  a  cause  of 
nosocomial  infections,  especially  in 
intensive care units (ICUs). In South 
Korea, Acinetobacter spp. was ranked 
as  the  third  most  frequently  found 
pathogen in ICUs (1). With the emer-
gence  of  multidrug-resistant  (MDR) 
or  pandrug-resistant  (PDR)  isolates, 
few drugs are now available to treat 
MDR  or  PDR  Acinetobacter  infec-
tions; polymyxins are the only thera-
peutic option in many cases (2). Cur-
rent polymyxin resistance rates among 
Acinetobacter isolates are low world-
wide (3). We report the emergence of 
extreme drug resistance (XDR) in A. 
baumannii  isolates  from  patients  in 
ICUs of Samsung Medical Center in 
Seoul,  South  Korea.  These  isolates 
were resistant to all tested antimicro-
bial drugs, including polymyxin B and 
colistin,  to  which  PDR  isolates  are 
normally susceptible.
Sixty-three  nonduplicate  Acine-
tobacter spp. isolates were collected 
from the ICUs from April through No-
vember  2007.  Species  identification 
was performed based on partial RNA 
polymerase β-subunit gene sequences, 
amplified  rDNA  restriction  analysis, 
and the gyrase B gene–based multi-
plex PCR method (3). Forty-four iso-
lates were identified as A. baumannii: 
9 as genomic species 3, six as genomic 
species 13TU, 2 as A. baumannii-like 
species, and 1 each as A. junnii and ge-
nomic species 10.
In vitro susceptibility testing was 
performed and interpreted by using the 
broth microdilution method according 
to the Clinical and Laboratory Stan-
dards Institute guidelines (4). Colistin 
and polymyxin B resistances were de-
fined as MIC >4 mg/L (4). MDR was 
defined as characterized by resistance 
to >3 classes of antimicrobial drugs, 
and PDR was defined as characterized 
by resistance to all antimicrobial drugs, 
regardless of colistin and polymyxin 
B susceptibility. XDR was defined as 
resistance to all antimicrobial drugs. 
Multilocus  sequence  typing  (MLST) 
and  pulsed-field  gel  electrophoresis 
(PFGE) were performed for all PDR 
isolates  according  to  previously  de-
scribed methods (5,6). Genes encod-
ing oxacillinases, such as those classi-
fied as OXA-23-like, OXA-24/40-like, 
OXA-51-like, and OXA-58-like, were 
detected as previously described (7). 
PCR and sequence analyses were per-
formed to detect and characterize the 
other  antimicrobial  resistance  genes, 
according to methods reported (8).